210 related articles for article (PubMed ID: 25604267)
1. Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms.
Espasandin YR; Glembotsky AC; Grodzielski M; Lev PR; Goette NP; Molinas FC; Marta RF; Heller PG
J Thromb Haemost; 2015 Apr; 13(4):631-42. PubMed ID: 25604267
[TBL] [Abstract][Full Text] [Related]
2. The gene expression signature of anagrelide provides an insight into its mechanism of action and uncovers new regulators of megakaryopoiesis.
Ahluwalia M; Butcher L; Donovan H; Killick-Cole C; Jones PM; Erusalimsky JD
J Thromb Haemost; 2015 Jun; 13(6):1103-12. PubMed ID: 25851510
[TBL] [Abstract][Full Text] [Related]
3. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia.
Tomer A
Blood; 2002 Mar; 99(5):1602-9. PubMed ID: 11861274
[TBL] [Abstract][Full Text] [Related]
4. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.
Tefferi A; Silverstein MN; Petitt RM; Mesa RA; Solberg LA
Semin Thromb Hemost; 1997; 23(4):379-83. PubMed ID: 9263355
[TBL] [Abstract][Full Text] [Related]
5. Anagrelide represses GATA-1 and FOG-1 expression without interfering with thrombopoietin receptor signal transduction.
Ahluwalia M; Donovan H; Singh N; Butcher L; Erusalimsky JD
J Thromb Haemost; 2010 Oct; 8(10):2252-61. PubMed ID: 20586925
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans.
Mazur EM; Rosmarin AG; Sohl PA; Newton JL; Narendran A
Blood; 1992 Apr; 79(8):1931-7. PubMed ID: 1562721
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures.
Wang G; Franklin R; Hong Y; Erusalimsky JD
Br J Pharmacol; 2005 Oct; 146(3):324-32. PubMed ID: 16041400
[TBL] [Abstract][Full Text] [Related]
8. [Anagrelide--new antiplatelet drug].
Robak T; Treliński J; Hołub A
Acta Haematol Pol; 1994; 25(4):309-15. PubMed ID: 7847031
[TBL] [Abstract][Full Text] [Related]
9. Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation.
Lane WJ; Hattori K; Dias S; Peerschke EI; Moore MA; Blanset DL; Lang PC; Petrone M; Rafii S
Exp Hematol; 2001 Dec; 29(12):1417-24. PubMed ID: 11750100
[TBL] [Abstract][Full Text] [Related]
10. [Anagrelide-induced changes of megakaryopoiesis during therapy of chronic myeloproliferative disorders with thrombocythemia].
Thiele J; Kvasnicka HM; Schmitt-Gräff A
Pathologe; 2002 Nov; 23(6):426-32. PubMed ID: 12436295
[TBL] [Abstract][Full Text] [Related]
11. [Anagrelide in the treatment of thrombocythemia essential (ET)].
Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
[TBL] [Abstract][Full Text] [Related]
12. Enhancing functional platelet release in vivo from in vitro-grown megakaryocytes using small molecule inhibitors.
Jarocha D; Vo KK; Lyde RB; Hayes V; Camire RM; Poncz M
Blood Adv; 2018 Mar; 2(6):597-606. PubMed ID: 29545255
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human primary megakaryocyte differentiation by anagrelide: a gene expression profiling analysis.
Sakurai K; Fujiwara T; Hasegawa S; Okitsu Y; Fukuhara N; Onishi Y; Yamada-Fujiwara M; Ichinohasama R; Harigae H
Int J Hematol; 2016 Aug; 104(2):190-9. PubMed ID: 27084257
[TBL] [Abstract][Full Text] [Related]
14. Paracrine regulation of megakaryo/thrombopoiesis by macrophages.
D'Atri LP; Pozner RG; Nahmod KA; Landoni VI; Isturiz M; Negrotto S; Schattner M
Exp Hematol; 2011 Jul; 39(7):763-72. PubMed ID: 21549176
[TBL] [Abstract][Full Text] [Related]
15. Effects of anagrelide on megakaryopoiesis and platelet production.
Thiele J; Kvasnicka HM; Schmitt-Graeff A
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):352-61. PubMed ID: 16810611
[TBL] [Abstract][Full Text] [Related]
16. The effects of anagrelide on human megakaryocytopoiesis.
Solberg LA; Tefferi A; Oles KJ; Tarach JS; Petitt RM; Forstrom LA; Silverstein MN
Br J Haematol; 1997 Oct; 99(1):174-80. PubMed ID: 9359521
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes.
Murai K; Kowata S; Shimoyama T; Yashima-Abo A; Fujishima Y; Ito S; Ishida Y
Eur J Haematol; 2014 Oct; 93(4):290-6. PubMed ID: 24750292
[TBL] [Abstract][Full Text] [Related]
18. Anagrelide: what was new in 2004 and 2005?
Petrides PE
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
[TBL] [Abstract][Full Text] [Related]
19. Anagrelide and Mutational Status in Essential Thrombocythemia.
Iurlo A; Cattaneo D; Orofino N; Bucelli C; Fabris S; Cortelezzi A
BioDrugs; 2016 Jun; 30(3):219-23. PubMed ID: 27041108
[TBL] [Abstract][Full Text] [Related]
20. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
Balduini CL; Bertolino G; Noris P; Ascari E
Haematologica; 1992; 77(1):40-3. PubMed ID: 1398280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
